3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Neoplasms
8
Melanoma
8
Pancreatic Neoplasms
7
Neoplasm Metastasis
5
Carcinoma, Non-Small-Cell Lung
5
Uterine Cervical Neoplasms
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumor
2
Sarcoma
2
Recurrence
2
Liver Neoplasms
2
Glioblastoma
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Advanced Solid Tumor
2
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Salivary Gland Neoplasms
1
Refractory or Recurrent Solid Tumor
1
Pelvic Neoplasms
1
Ovarian Neoplasms
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Mesothelioma, Malignant
1
Interventions
Oxaliplatin
16
Irinotecan
12
Fluorouracil
12
Leucovorin
10
Bevacizumab
8
pembrolizumab
7
Cetuximab
7
Capecitabine
7
Nivolumab
5
Gemcitabine
5
Cyclophosphamide
5
fludarabine
4
aldesleukin
4
Panitumumab
4
Folfox protocol
4
oblimersen
3
Interleukin-2
3
selpercatinib
2
poly ICLC
2
labetuzumab
2
dehydroftorafur
2
conatumumab
2
cemiplimab
2
bintrafusp alfa protein, human
2
Tomography, X-Ray Computed
2
Specimen Handling
2
Receptor Protein-Tyrosine Kinases
2
Radiotherapy
2
Levoleucovorin
2
Injections
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Colonic Neoplasms
×
spartalizumab
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts